Your browser doesn't support javascript.
loading
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.
Rischin, Danny; Gil-Martin, Marta; González-Martin, Antonio; Braña, Irene; Hou, June Y; Cho, Daniel; Falchook, Gerald S; Formenti, Silvia; Jabbour, Salma; Moore, Kathleen; Naing, Aung; Papadopoulos, Kyriakos P; Baranda, Joaquina; Fury, Wen; Feng, Minjie; Stankevich, Elizabeth; Li, Jingjin; Yama-Dang, N Alice; Yoo, Suk-Young; Lowy, Israel; Mathias, Melissa; Fury, Matthew G.
  • Rischin D; Department of Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia. Electronic address: Danny.Rischin@petermac.org.
  • Gil-Martin M; Institut Català d'Oncologia-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
  • González-Martin A; Clinica Universidad de Navarra, Madrid, Spain.
  • Braña I; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Hou JY; Division of Gynecologic Oncology, Columbia University Medical Center, New York, NY, USA.
  • Cho D; Perlmutter Cancer Center at NYU Langone Medical Center, New York, NY, USA.
  • Falchook GS; Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.
  • Formenti S; Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.
  • Jabbour S; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Moore K; Stephenson Cancer Center at the University of Oklahoma Health Sciences Center/Sarah Cannon Research Institute, Oklahoma City, OK, USA.
  • Naing A; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Papadopoulos KP; START, San Antonio, TX, USA.
  • Baranda J; Early Phase Program Clinical Research Center, University of Kansas Cancer Center, Fairway, KS, USA.
  • Fury W; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Feng M; Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA.
  • Stankevich E; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Li J; Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA.
  • Yama-Dang NA; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Yoo SY; Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA.
  • Lowy I; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Mathias M; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Fury MG; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Gynecol Oncol ; 159(2): 322-328, 2020 11.
Article en En | MEDLINE | ID: mdl-32917410
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas / Adenocarcinoma / Neoplasias del Cuello Uterino / Anticuerpos Monoclonales Humanizados / Antineoplásicos Inmunológicos Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas / Adenocarcinoma / Neoplasias del Cuello Uterino / Anticuerpos Monoclonales Humanizados / Antineoplásicos Inmunológicos Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Año: 2020 Tipo del documento: Article